Zacks: Emmaus Life Sciences (NASDAQ:EMMA) Given Consensus Recommendation of “Strong Buy” by Brokerages

Emmaus Life Sciences (NASDAQ:EMMA) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus price target of $24.00 for the company, according to Zacks. Zacks has also given Emmaus Life Sciences an industry rank of 58 out of 255 based on the ratings given to related companies.

A number of brokerages recently commented on EMMA. Zacks Investment Research raised Emmaus Life Sciences from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research report on Tuesday, November 5th. Dawson James lowered Emmaus Life Sciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, September 24th.

Emmaus Life Sciences stock traded down $0.03 during midday trading on Wednesday, reaching $2.12. The stock had a trading volume of 3,219 shares, compared to its average volume of 51,239. Emmaus Life Sciences has a 12 month low of $1.33 and a 12 month high of $12.90. The company has a market cap of $174.50 million, a P/E ratio of -0.32 and a beta of 2.91. The business has a fifty day moving average price of $2.75. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.44 and a quick ratio of 1.44.

In related news, CEO Yutaka Niihara purchased 19,100 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was acquired at an average price of $2.48 per share, for a total transaction of $47,368.00. Also, COO Willis C. Lee purchased 11,000 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were bought at an average price of $2.48 per share, with a total value of $27,280.00. Insiders have acquired a total of 187,334 shares of company stock valued at $714,605 in the last quarter. Company insiders own 36.88% of the company’s stock.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement.

Read More: Why is total return important?

Get a free copy of the Zacks research report on Emmaus Life Sciences (EMMA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with's FREE daily email newsletter.